A potential anti-parkinson drug, N-n-propyl-N-n-butyl-beta-(3,4-dihydroxyphenyl)ethylamine hydrochloride, and its effects in intact and nigra-lesioned rats.
D000818:Animals; D000978:Antiparkinson Agents / Q000097:blood / Q000138:chemical synthesis* / Q000494:pharmacology; D001522:Behavior, Animal / Q000187:drug effects*; D002394:Catechol O-Methyltransferase / Q000097:blood; D065098:Catechol O-Methyltransferase Inhibitors; D004298:Dopamine / Q000031:analogs & derivatives* / Q000097:blood / Q000138:chemical synthesis / Q000494:pharmacology; D006801:Humans; D008297:Male; D008745:Methylation; D011748:Pyrogallol / Q000494:pharmacology; D051381:Rats; D013239:Stereotyped Behavior / Q000187:drug effects; D013378:Substantia Nigra / Q000502:physiology*
D000978:Antiparkinson Agents; D065098:Catechol O-Methyltransferase Inhibitors; D011748:Pyrogallol; C016080:N-n-propyl-N-n-butyl-beta-dopamine; D002394:Catechol O-Methyltransferase; D004298:Dopamine